Area of research
Oncology · Molecular Biology
Research interest
Research interests include Bone health and treatments, Bone Metabolism and Diseases, Cancer, Lipids, and Metabolism, and Radiopharmaceutical Chemistry and Applications.
Gut-to-brain signaling restricts dietary protein intake during recovery from catabolic states
Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase
High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer
Endocrine health in survivors of adult-onset cancer
The mevalonate pathway in breast cancer biology
Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis
Long-term bone health in childhood cancer survivors: underappreciated and undertreated?
The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology
Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
Evolving functions of Dickkopf-1 in cancer and immunity
High serum levels of periostin are associated with a poor survival in breast cancer
Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors
Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases
Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer
Skeletal health in patients following allogeneic hematopoietic cell transplantation
Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
Pharmacological mechanisms of therapeutics
Extraskeletal effects of RANK ligand
Bone health during endocrine therapy for cancer
Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin
Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer
Role of WNT5A receptors FZD5 and RYK in prostate cancer cells
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer
Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients
p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells
Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells